Pharmacoeconomic Analysis of Stress Ulcer Prophylaxis for Critically Ill Patients
Authors:
- 1 May 1996
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 9 (5) , 455-465
Abstract
The objective of this study was to evaluate the economic outcomes of drug options for stress ulcer prophylaxis in critically ill and/or intensive care unit patients. Decision analytic modelling was used to compare the costs of stress ulcer prophylaxis and possible clinical outcomes [acute upper gastrointestinal bleeding (AUGB) and nosocomial pneumonia]. The regimens evaluated were: antacids, histamine H2 receptor antagonists (H2RAS), sucralfate and no prophylaxis. The results of published studies were pooled to determine the expected probability of AUGB and nosocomial pneumonia following stress ulcer prophylaxis with each of the agents under study. The costs of stress ulcer prophylaxis, treatment of AUGB and treatment of nosocomial pneumonia were identified from various sources. Sucralfate was the least costly agent for stress ulcer prophylaxis. The average net costs per patient for sucralfate, antacids, no prophylaxis and H2RAS were $US1457, $US1737, $US2268, and $US2638 to $US2712, respectively (1994 dollars). No prophylaxis was found to be less costly than giving H2RAS. Sucralfate and antacids, which induced net savings of $US7373 and $US4321 per case of AUGB averted, respectively, were more cost effective than H2RAS. Sensitivity and threshold analyses revealed that the results were constant over a wide range of cost and probability values. Break-even analysis suggested that sucralfate was the optimal agent for stress ulcer prophylaxis unless the acquisition cost of a prophylactic course of sucralfate was >$US304.05 per patient. At that point, antacids become the optimal agent. Based on this analysis, sucralfate may be the most cost-effective agent for stress ulcer prophylaxis in critically ill or intensive care patients.Keywords
This publication has 44 references indexed in Scilit:
- Valuation of medical resource units collected in health economic studies.1994
- Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumoniaCritical Care Medicine, 1993
- Gastric colonization and pneumonia in intubated critically ill patients receiving stress ulcer prophylaxisCritical Care Medicine, 1992
- Sucralfate suspension versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patientsThe American Journal of Medicine, 1987
- Prevention of acute stress bleeding with sucralfate, antacids, or cimetidine: A controlled study with pirenzepine as a basic medicationThe American Journal of Medicine, 1985
- Prophylaxis of upper gastrointestinal hemorrhage in patients requiring mechanical ventilationCritical Care Medicine, 1982
- Cimetidine and antacid prophylaxis of acute upper gastrointestinal bleeding in high risk patientsThe American Journal of Surgery, 1981
- THE PREVENTION OF UPPER GASTROINTESTINAL-TRACT BLEEDING IN PATIENTS IN AN INTENSIVE-CARE UNIT1981
- Randomized Prospective Evaluation of Cimetidine and Antacid Control of Gastric pH in the Critically IIIAnnals of Surgery, 1980
- ANTACID CONTROL OF COMPLICATIONS FROM ACUTE GASTRODUODENAL DISEASE AFTER BURNS1976